A systematic review and meta-analysis explored the relationship between androgen deprivation therapy and risk for heart failure in men with prostate cancer who were treated with ADT. A meta-analysis ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

Serum testosterone (T) recovery to normal levels is associated with a significant improvement in overall survival in patients ...

Untreated prostate cancer can sometimes cause erectile dysfunction (ED). However, ED is more commonly associated with ...

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes.

The PORTOS assay could indicate when or when not to offer dose-escalated radiation for localized prostate cancer.

For patients with advanced prostate cancer (aPC), completion of a 12-week supervised exercise regimen leads to a significant ...

Testosterone therapy after prostate cancer surgery does not appear to increase biochemical recurrence (BCR) risk in patients with low-risk disease, investigators report.

When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen ...

Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

OPTYX study shows many patients with advanced prostate cancer preferred oral relugolix over injectables for androgen deprivation therapy.